Trial Profile
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms SCALE IBT
- Sponsors Novo Nordisk
- 18 Mar 2019 Results of a pre-specified secondary analysis assessing athe effect of liraglutide 3.0 mg on weight loss, presented at the 101st Annual Meeting of the Endocrine Society
- 18 Mar 2019 Results of a pre-specified exploratory sub-analysis determining the individual contributions of adherence to study medication, and to the adjunct diet and physical activity interventions on weight change, presented at the 101st Annual Meeting of the Endocrine Society.
- 18 Mar 2019 Primary endpoint (Proportion of subjects losing at least 5% of baseline body weight) has been met, according to the results presented at the 101st Annual Meeting of the Endocrine Society.